Polyrizon Ltd. Signs Agreement with Preclinical CRO for Clinical Development Program

Polyrizon Ltd. has signed an agreement with a leading global preclinical Contract Research Organization (CRO) to conduct biocompatibility studies in accordance with ISO 10993 standards and GLP requirements. These studies are a crucial step in Polyrizon's clinical development program, which aims to advance its intranasal administrated solutions toward initiating clinical trials. The studies, expected to commence in the second quarter of 2026, will include assessments for cytotoxicity, sensitization, intracutaneous reactivity, acute systemic toxicity, and pyrogenicity. This collaboration is part of Polyrizon's broader strategy, which includes recent GMP production of clinical trial material, a successful FDA pre-submission meeting, and positive preclinical data. The company believes this partnership strengthens their regulatory strategy and supports their timeline for initiating clinical trials later in 2026. Polyrizon is developing proprietary nasal medical device technology for drug delivery and as a protective barrier against viruses and allergens.